Brief: Atreca Announces First Patient Dosed In Phase 1B Clinical Trial Of ATRC-101
13/02/2020 22:48
Feb 13 (Reuters) - Atreca Inc BCEL.O :
* ATRECA ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B CLINICAL
TRIAL
OF ATRC-101 IN PATIENTS WITH SELECT SOLID TUMORS
* ATRECA INC - TRIAL WILL ALSO EVALUATE POTENTIAL BIOMARKERS
AND
INITIAL SIGNALS OF CLINICAL ACTIVITY OF ATRC-101
Source text for Eikon: ID:nGNX1Fg97v
Further company coverage: BCEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atreca
See all newsBrief: Baker Bros Advisors Reports 19.99% Passive Stake In Atreca As Of Dec 31, 2023 - SEC Filing
Brief: Immunome To Acquire Antibody-Related Assets And Materials From Atreca
Brief: Atreca Says On Dec 19 Asset Sale And Other Transactions Contemplated By Agreement, Board Approved Liquidation And Dissolution Of Co
Brief: Atreca Q3 basic EPS USD -0.92
Brief: Atreca Announces Agreement To Terminate Lease And Departure Of CFO Herb Cross